<?xml version="1.0" encoding="UTF-8"?>
<xml>
  <records>
    <record>
      <source-app name="Horizon">Horizon</source-app>
      <rec-number>1</rec-number>
      <foreign-keys>
        <key app="Horizon" db-id="PAR00010187">1</key>
      </foreign-keys>
      <ref-type name="Journal Article">17</ref-type>
      <work-type>ACL : Articles dans des revues avec comité de lecture répertoriées par l'AERES</work-type>
      <contributors>
        <authors>
          <author>
            <style face="normal" font="default" size="100%">Thiam, M.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Diop-Ndiaye, H.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Diouf, A. D.</style>
          </author>
          <author>
            <style face="bold" font="default" size="100%">Vidal, Nicole</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Ndiaye, O.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Ndiaye, I.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Ngom-Gueye, N. F.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Diallo, S.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Diongue, O. D.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Camara, M.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Seck, A.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Mboup, S.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Toure-Kane, C.</style>
          </author>
        </authors>
      </contributors>
      <titles>
        <title>HIV-1 genetic diversity and drug resistance among Senegalese patients in the public health system</title>
        <secondary-title>Journal of Clinical Microbiology</secondary-title>
      </titles>
      <pages>578-584</pages>
      <keywords>
        <keyword>SENEGAL</keyword>
      </keywords>
      <dates>
        <year>2013</year>
      </dates>
      <call-num>PAR00010187</call-num>
      <language>ENG</language>
      <periodical>
        <full-title>Journal of Clinical Microbiology</full-title>
      </periodical>
      <isbn>0095-1137</isbn>
      <accession-num>ISI:000314108000028</accession-num>
      <number>2</number>
      <electronic-resource-num>10.1128/jcm.02452-12</electronic-resource-num>
      <urls>
        <related-urls>
          <url>https://www.documentation.ird.fr/hor/PAR00010187</url>
        </related-urls>
        <pdf-urls>
          <url>https://www.documentation.ird.fr/intranet/publi/2022-12/010087035.pdf</url>
        </pdf-urls>
      </urls>
      <volume>51</volume>
      <remote-database-provider>Horizon (IRD)</remote-database-provider>
      <abstract>In this study, we investigated the prevalence of human immunodeficiency virus type 1 (HIV-1) drug resistance mutations and genetic variability among Senegalese patients undergoing highly active antiretroviral therapy (ART) in the public health system. We conducted a cross-sectional study of 72 patients with suspected therapeutic failure. HIV-1 genotyping was performed with Viroseq HIV-1 Genotyping System v2.0 or the procedure developed by the ANRS AC11 resistance study group, and a phylogenetic analysis was performed. The median follow-up visit was at 40 (range, 12 to 123) months, and the median viral load was 4.67 (range, 3.13 to 6.94) log(10) copies/ml. The first-line therapeutic regimen was nucleoside reverse transcriptase inhibitors (NRTIs) plus efavirenz (EFV) or NRTIs plus nevirapine (NVP) (54/72 patients; 75%), and the second-line therapy was NRTIs plus a protease inhibitor (PI/r) (18/72; 25%). Fifty-five patients (55/72; 76.39%) had at least one drug resistance mutation. The drug resistance rates were 72.22 and 88.89% for the first-line and second-line ARTs, respectively. In NRTI mutations, thymidine analog mutations (TAMs) were found in 50.79% and the M184V mutation was found in 34.92% of the samples. For non-NRTI resistance, we noted a predominance of the K103N mutation (46.27%). For PI/r, several cases of mutations were found with a predominance of M46I and L76V/F at 24% each. The phylogenetic analysis revealed CRF02_AG as the predominant circulating recombinant form (43/72; 59.72%). We found a high prevalence of resistance mutations and a high rate of TAMs among Senegalese patients in the public health system. These findings emphasize the need to improve virological monitoring in resource-limited settings.</abstract>
      <custom6>052 ; 050</custom6>
      <custom1>UR233</custom1>
      <custom7>Sénégal</custom7>
    </record>
  </records>
</xml>
